Larimar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Larimar Therapeutics

15/05/2023 14:32

* Larimar Therapeutics Inc  LRMR.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 25 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Larimar Therapeutics Inc's reported EPS for the quarter
was a
loss of 15 cents​.
    * The mean earnings estimate of analysts had risen by
about 18.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Larimar Therapeutics Inc shares had risen by 11.7% this
quarter and gained 22.5% so far this year.
    * The company reported a quarterly loss of $6.53 million.
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $13.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.25          -0.15          Beat
 Dec. 31 2022      -0.27          -0.21          Beat
 Sep. 30 2022      -0.42          -0.37          Beat
 Jun. 30 2022      -0.57          -0.47          Beat